Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Urine Test for Tuberculosis Needs Improving

By LabMedica International staff writers
Posted on 17 Aug 2011
A noninvasive urinary assay for tuberculosis (TB) is not accurate enough to be used for routine diagnosis of active tuberculosis. More...


The assay works by detecting the heat-stable glycolipid that is present in the cell walls of Mycobacterium tuberculosis and released from active or degrading cells during an infection.

A meta-analysis of and systematic review was conducted on the use of the lipoarabinomannan (LAM) urinary assay for the diagnosis of active TB. Scientists pooled data from nine studies that compared LAM urine testing to an accepted reference, such as positive culture or nucleic acid amplification for TB. Included were trials from Sweden, Ethiopia, Tanzania, Zimbabwe, South Africa, and India, with a total of close to 3,000 people.

In seven studies that only included microbiologically confirmed cases of TB, LAM sensitivity ranged from 13% to 93%, and specificity was 87% to 99%. Sensitivity also varied widely in two additional analyses that counted clinically confirmed cases as either positive or negative for TB. The team stated the assay was more accurate in HIV-positive patients. In that group, its sensitivity for TB was 3% to 53% higher than in HIV-negative individuals, with similar specificity. Sensitivity was highest when immunosuppression was advanced, in which case there might be more LAM in the urine for detection.

Dick Menzies, MD, a lead author of the study from the Montreal Chest Clinic (Montreal, QC, Canada), said, "The LAM urine assay has many characteristics which make it a potentially useful rule-in TB diagnostic, but this review found inadequate sensitivity to use the LAM assay for the diagnosis of TB in unselected cohorts." However, further studies are warranted to evaluate the added value of the LAM assay, known as Clearview TB ELISA (Inverness Medical Innovations; Princeton, NJ, USA) in the diagnosis of active TB. It is especially important for individuals with advanced HIV and in children as well as to assess newer versions of this test with technical advances compared to those in the study. The review was published online on July 4, 2011, in the European Respiratory Journal.

Related Links:

Montreal Chest Clinic
Inverness Medical Innovations



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.